Search
Evaxion Biotech A/S
EVAXAdd to Watchlist
3.920USD
-0.200-4.85%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
32.69MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-4.85%
5 Days
-9.68%
1 Month
-5.31%
6 Months
-28.21%
Year to Date
-17.82%
1 Year
+125.11%
TradingKey Stock Score of Evaxion Biotech A/S
Currency: USD Updated: 2026-05-15Key Insights
Evaxion Biotech A/S's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 189 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.25.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evaxion Biotech A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Evaxion Biotech A/S Highlights
StrengthsRisks
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 10212.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.53M.
Undervalued
The company’s latest PE is -18.85, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 323.61K shares, increasing 1.65% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
11.250
Target Price
+173.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Evaxion Biotech A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Evaxion Biotech A/S Info
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Ticker SymbolEVAX
CompanyEvaxion Biotech A/S
CEO
Websitehttps://evaxion.ai/
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78119.720
-111.280 (-0.14%)
422.240
-21.060 (-4.75%)
